Cholangiocarcinoma The Lancet Nataliya Razumilava, MD, Prof Gregory J Gores, MD The Lancet Volume 383, Issue 9935, Pages 2168-2179 (June 2014) DOI: 10.1016/S0140-6736(13)61903-0 Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 1 Integrative approach to (A) diagnosis and (B) individualised medicine in cholangiocarcinoma FISH=fluorescence in-situ hybridisation. SDS-PAGE=sodium dodecyl sulfate polyacrylamide gel electrophoresis. The Lancet 2014 383, 2168-2179DOI: (10.1016/S0140-6736(13)61903-0) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 2 Potential cells of origin in intrahepatic cholangiocarcinoma PV=portal vein. HA=hepatic artery. BD=bile duct. HC=hepatic cell. The Lancet 2014 383, 2168-2179DOI: (10.1016/S0140-6736(13)61903-0) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 3 Approach to management of (A) intrahepatic and (B) perihilar cholangiocarcinoma HCC=hepatocellular carcinoma. CA 19-9=carbohydrate antigen 19-9. Reproduced with modifications from reference 69 by permission of Elsevier. The Lancet 2014 383, 2168-2179DOI: (10.1016/S0140-6736(13)61903-0) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 4 Imaging studies of a patient with perihilar cholangiocarcinoma of the left hepatic duct Note prominent left hepatic duct dilatation with obstruction of the left hepatic duct system on the CT scan (A), MRI (B), endoscopic retrograde cholangiography (C), and magnetic resonance cholangiography (D); (D) also shows bilateral obstruction of the biliary system at the right and left hepatic bile duct confluence. The Lancet 2014 383, 2168-2179DOI: (10.1016/S0140-6736(13)61903-0) Copyright © 2014 Elsevier Ltd Terms and Conditions